Personalised organoid profiling from biopsy for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The protocol collects small tissue samples by echo‑endoscopic fine‑needle biopsy (EUS‑FNB) and blood samples to generate patient‑derived organoids (PDOs) from pancreatic lesions. These PDOs will be characterised for morphology, growth/proliferation, and molecular features and used for functional testing including drug sensitivity screens. The goal is to validate whether reliable organoids can be made from routine diagnostic biopsies rather than only from surgical resections. Successful generation and profiling could expand personalised testing to the majority of PDAC patients who are not surgical candidates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient over 18 years of age.
* Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB).
* Suspicion of pancreatic lesion
* Patient able to receive and understand information relating to the research protocol and to give consent.
* Patient affiliated to the French social security system.

Exclusion Criteria:

* Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB).
* Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB.
* Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN)
* Patient with acute pancreatitis within 4 weeks prior to EUS
* Pregnant or breast-feeding patient
* Patient under court protection.
* Patient under guardianship or curatorship.
* Patient in a situation of social vulnerability.
* Patient under legal protection or unable to express his/her opposition.

Where it's running

• Centre d'Endoscopie Digestive
  Strasbourg, France Recruiting
• Department of hepato-gastroenterology
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Armelle TAKEDA
• Email: armelle.takeda@ihu-strasbourg.eu
• Phone: +33390413608

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

  A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.

  Recruiting Fondazione Policlinico Universitario Campus Bio-Medico · Rome, Italy · NCT07659639

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Personalised Functional Profiling in colorectal cancer and pancreatic cancer

  This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.

  Recruiting Luxembourg Institute of Health · Luxembourg, Luxembourg · NCT07500259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.